Tandem Diabetes Gets FDA Nod for Control-IQ+ System for Type 2 Diabetes

Published 9 hours agoTNDM

Tandem Diabetes Gets FDA Nod for Control-IQ+ System for Type 2 Diabetes

Tandem Diabetes Care has achieved a significant milestone with the FDA's clearance of its Control-IQ+ automated insulin delivery system for adults with type 2 diabetes. This approval extends the company's reach from its traditional type 1 diabetes market to now include type 2 diabetes, as reported by nasdaq.com. This marks a crucial development for millions of individuals reliant on intensive insulin therapy.

In clinical trials, the Control-IQ+ system demonstrated impressive results, reducing A1C levels by 0.9% among over 300 trial participants, whereas a control group only saw a reduction of 0.3%, according to stocktitan.net. With over two million Americans managing type 2 diabetes through intensive insulin therapy, this approval substantially expands Tandem's market reach. The system's enhanced features, such as extended bolus capabilities and temporary basal rate adjustments, offer tailored solutions to meet diverse patient needs, notes drugdeliverybusiness.com.

Looking forward, Tandem Diabetes Care plans to showcase the full results of their pivotal study at the 18th International Conference on Advanced Technologies & Treatments for Diabetes in Amsterdam in March 2025. This strategic move underscores Tandem's commitment to advancing diabetes care and expanding its product application across different diabetes types.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Visa Completes Exchange Offer for Class B-1 Stock Confidently

Visa Completes Exchange Offer for Class B-1 Stock Confidently

12 minutes agoV

Visa has successfully concluded its Exchange Offer for Class B-1 common stock, wrapping up the offer on May 6, 2024. The company announced the results following the offer's expiration on May 3, 2024. Notably, approximately 98% of outstanding Class B-1 shares participated, amounting to 240,677,470 shares, according to Visa's announcements. In the exchange, Visa issued 120,338,683 shares of Class B-2 common stock while also providing 47,759,832 shares of Class C common stock. Cash was offered in lieu of fractional shares, based on the closing price of Class A common stock, which was $268.49 on the expiration date. Crucially, Visa opted not to engage in any stabilization or manipulation of share prices during this offer period, as reported by contracts.justia.com. This strategic financial maneuver by Visa aimed to unlock liquidity for its shareholders by releasing transfer restrictions on its Class B stock. By doing so, Visa not only potentially reduces overhang risks but also showcases its ongoing commitment to market stability and reinforcing shareholder trust.

Apple Faces Legal Hurdle Over App Store Practices

Apple Faces Legal Hurdle Over App Store Practices

27 minutes agoAAPL

Apple Inc. encountered a major legal hurdle when U.S. District Judge Yvonne Gonzalez Rogers found the company in violation of a court order from April 30, 2025. The ruling stated that Apple impeded competition by imposing a 27% commission on external transactions and restricting links to external purchases. As a result, Apple's finance VP, Alex Roman, and the company were referred to federal prosecutors for potential criminal contempt, according to Reuters. In response to this decision, Epic Games, known for its ongoing antitrust confrontation with Apple, announced its intention to bring "Fortnite" back to the App Store. The decision is seen as a triumph for developers and consumers, marking a shift in the dynamics between Apple and third-party app developers. Meanwhile, Apple's stock saw a slight uptick, trading at $212.50 with a 0.544% increase from its previous close as of May 1, 2025. Apple has communicated its intent to appeal the ruling, though it has agreed to comply with the current court order in the meantime. The company remains at the center of discussions about fair competition practices, especially concerning how it manages the App Store, which has been a significant point of contention in its legal battles with app developers.

CVS Shares Surge 12% After CMA Ends Investigation

CVS Shares Surge 12% After CMA Ends Investigation

42 minutes agoCVS

Shares of CVS Group plc jumped by 12% after the UK’s Competition and Markets Authority (CMA) closed its investigation into the company. The probe, which began in May 2024, was part of a broader examination into the UK’s £5 billion veterinary sector, focusing on concerns about pricing and transparency. There were initial fears that the CMA might enforce stringent measures like capping prescription fees or demanding asset sell-offs, as reported by fool.co.uk. However, the situation took a positive turn as CVS offered to sell its subsidiary, The Vet, leading to the conclusion of the investigation. This move was formally accepted by the CMA, calming investor concerns and driving the recent surge in share price, as detailed on advfn.com. CVS has been strategically reshaping its portfolio, having already offloaded loss-making operations in the Netherlands and Republic of Ireland to concentrate on more profitable markets. According to lse.co.uk, CVS is steadfast in its growth ambitions, including plans to expand within the Australian veterinary market, while maintaining support for the CMA's ongoing sector review.

Ryanair May Look Beyond Boeing Amid Tariff Concerns

Ryanair May Look Beyond Boeing Amid Tariff Concerns

57 minutes agoBA

Ryanair CEO Michael O'Leary has indicated that the airline might explore alternatives to Boeing for its aircraft orders if U.S. tariffs significantly drive up costs. This development comes as Ryanair is completing its order of 210 Boeing 737 MAX jets, with 29 planes still expected by March of next year, according to Reuters. In addition to their current order, Ryanair holds 150 firm orders for the Boeing MAX 10 model, with options for 150 more, starting in 2027. Concerns have been raised about potential increases in aircraft prices due to U.S. tariffs, pushing Ryanair to consider other manufacturers. O'Leary mentioned that they haven't discussed with Chinese manufacturer COMAC since 2011, but would consider them if their planes were priced 10%-20% lower than those of Boeing's competitor Airbus. U.S. Representative Raja Krishnamoorthi has voiced concerns over the possibility of Ryanair purchasing Chinese-manufactured planes, citing potential national security risks. Meanwhile, Boeing is actively working to address Ryanair's concerns, focusing on improving the quality and delivery performance of the 737 model, as reported by Aeroxplorer.